Sartorius Stedim Biotech (Sartorius Stedim Biotech) Change In Receivables : $174 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sartorius Stedim Biotech Change In Receivables?

Sartorius Stedim Biotech's change in receivables for the quarter that ended in Dec. 2023 was $38 Mil. It means Sartorius Stedim Biotech's Accounts Receivable declined by $38 Mil from Sep. 2023 to Dec. 2023 .

Sartorius Stedim Biotech's change in receivables for the fiscal year that ended in Dec. 2023 was $177 Mil. It means Sartorius Stedim Biotech's Accounts Receivable declined by $177 Mil from Dec. 2022 to Dec. 2023 .

Sartorius Stedim Biotech's Accounts Receivable for the quarter that ended in Dec. 2023 was $320 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sartorius Stedim Biotech's Days Sales Outstanding for the three months ended in Dec. 2023 was 37.93.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sartorius Stedim Biotech's liquidation value for the three months ended in Dec. 2023 was $-4,677 Mil.

Sartorius Stedim Biotech Change In Receivables Historical Data

The historical data trend for Sartorius Stedim Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Change In Receivables Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

4.27

-89.89

-98.64

-69.70

176.77

Sartorius Stedim Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															16.31	55.03	24.05	57.63	37.62

Sartorius Stedim Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $174 Mil.

Sartorius Stedim Biotech (OTCPK:SDMHF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sartorius Stedim Biotech's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	320.393	/	770.774	*	91
=	37.93

2. In Ben Graham's calculation of liquidation value, Sartorius Stedim Biotech's accounts receivable are only considered to be worth 75% of book value:

Sartorius Stedim Biotech's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	127.154	-	5525.3	+	0.75 * 320.393	+	0.5 * 962.268
=	-4,677

Sartorius Stedim Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SDMHF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SRTOY:USA DIM:Mexico DIMp:UK 0RG8:UK DIM:France 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.